SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
654Couldn't post this yesterday because the Merrill site was misbehaving: Celgtom pope-9/14/2005
653Courtesy of Forbes, some color on today's Pru downgrade: >>06.21.05, tuck-6/21/2005
652Drug Used for Symptoms Attacks Disease Too 15 May 2005, 4:24pm ET By MARILYNN FiloF-5/15/2005
651Petition Seeks Warning on Anticancer Medication [NYT] By GARDINER HARRIS PublDoc Bones-5/4/2005
650Revlimid(R) (Lenalidomide) Clinical Data From Interim Analysis of Pivotal Phase sim1-4/11/2005
649Merrill upgrade: Message 21178863tom pope-3/29/2005
648CELG related AACR abstracts. I hope I haven't missed any. abstractonline.cosim1-3/14/2005
647Adviser Soapbox Regulatory Roadblocks Ahead for Celgene Scott Gottlieb, M.D., 03sim1-3/8/2005
646REVLIMID(R) Pivotal Phase III Multiple Myeloma Trials Both Exceed Pre-Specified sim1-3/6/2005
645Clinical Data From Initial REVLIMID(TM) Study in Myelodysplastic Syndromes Reporsim1-2/9/2005
644[Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autoltuck-1/5/2005
643Deaths Mar Trial of Celgene's MDS Drug By Adam Feuerstein Senior Writer 11/1sim1-11/17/2004
642Celgene's Bright Financial Outlook 10.26.04, 4:25 PM ET [Forbes] Prudentialsim1-10/28/2004
641Thalidomide has some key features and drawbacks. First, it is an approved drug tBiomaven-10/27/2004
640I believe that answers to the different rationale you suggest is... 'yes'sim1-10/27/2004
639Can someone explain to me the rationale for trying to have 3 compounds approved Nate G-10/26/2004
638Celgene Receives FDA Approvable Letter for Thalomid sNDA Friday October 22, 5:59sim1-10/23/2004
637[CC-4047 and CC-5013 -- next generation thalidomide analogs] Full text editoriatuck-8/19/2004
636ECOG Phase III Study on Thalomid(R) Plus Dexamethasone Reports Clinical Benefit sim1-6/7/2004
635Thanks very much for the feedback. I can see that there may be little competitA.J. Mullen-4/30/2004
634Ashley, Thalidome chances in combination regime for mNSCLC are not clear at thiMiljenko Zuanic-4/29/2004
633Miljenko, and how about Thalidomide compared to Tarceva? The Phase 111 results A.J. Mullen-4/29/2004
632Appears that investors are not overly concerned about this failure. The questioMiljenko Zuanic-4/28/2004
631Celgene Announces Plans to Stop Phase III Trials In Melanoma Due to Lack of Effinigel bates-4/28/2004
63051% drop-out rate seems very high. Are doses much higher than those that were uA.J. Mullen-2/6/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News